Latest Industry Insights

CEL-SCI Corporation recently announced that it is utilizing LEAPS peptide technology in efforts to develop an immunotherapy against the novel coronavirus caused by SARS-CoV-2. Technology Networks, spoke with Daniel Zimmerman, Ph.D. Senior VP of Research, Cellular Immunology at CEL-SCI Corporation, to learn more about the LEAPS technology.

Technology Networks recently spoke with Dr Jacques Ravel (Chief Scientist of LUCA Biologics) and Luba Greenwood (CEO of LUCA Biologics) to learn more about what the vaginal microbiome is, how it can contribute to human pathology and the development of novel therapeutics in this space that are approaching clinical trials.

With the number of new cancer cases worldwide per year predicted to rise to 23.6 million by 2030, it seems as pertinent as ever that the disease is stopped early in its tracks. We spoke with Mike Fisher, Ph.D., Commercial Director of Oncimmune, to find out more about a trial utilizing a simple blood test for early detection of lung cancer.

Technology Networks recently had the pleasure of speaking with Bruce Steel, CEO Equillium, Inc. to learn more about how they are leveraging their comprehensive understanding of immunobiology to develop novel treatments for inflammatory and autoimmune disorders.

Technology Networks spoke with Jonathan Widdowson, Director of ProColl and Enterprise Fellow at the Royal Academy of Engineering Enterprise Hub, to learn more about how yeast can be used to manufacture collagens and the applications of this approach.

Technology Networks spoke with Isaku Tanida, Head of Protein and Pathway Technologies, Life Science at Merck to learn about Merck's ZooMAb® recombinant antibodies. These antibodies are developed from a B-cell immortalization technology which enables production in a variety of species.

Technology Networks recently spoke with Paul-Peter Tak, President & CEO, Kintai Therapeutics, to learn more about the anti-obesity agent the company is currently developing.

Technology Networks spoke with GenapSys to learn more about the sequencer which is "100x smaller and less expensive than legacy high-throughput sequencers" and how it can be applied to study the Coronavirus.

At the beginning of the year, direct-to-consumer (DTC) genetic testing company 23andMe announced that they have generated a bispecific antibody that blocks the IL-36 cytokine family associated with multiple inflammatory diseases. Technology Networks spoke with Christine Pai from 23andMe to find out more.

Introduced back in March 2019, Cell Mentor^TM is an online educational resource for biology students and researchers, created by Cell Signaling Technology and Cell Press. To open the resource up to even more scientists, a Chinese version of the site was recently launched.